Inhibitors of monocarboxylate transporters as host-directed antivirals against human adenoviruses

Human adenoviruses (HAdVs) are non-enveloped double-stranded DNA viruses that cause a wide range of typically mild, self-limiting infections in humans, but are associated with high morbidity and mortality in immunocompromised individuals. There are currently no approved antivirals specifically targeting HAdV infection. To identify novel anti-adenoviral compounds and host factors critical for infection, we screened a target-annotated library of 13,000 compounds, covering 1,763 known human targets, against HAdV type 11 in K562 cells. This screen yielded numerous anti-adenoviral compounds, many of which were kinase inhibitors, well known to also show antiviral activity. We instead focused on potent and selective inhibitors of monocarboxylate transporter 1 (MCT1) for further investigation. For 25 MCT1 inhibitors, antiviral activity correlated clearly with MCT1 inhibitory potency, indicating MCT1 inhibition as the likely mechanism. MCT1 exports lactate and is frequently overexpressed in cancers that rely on aerobic glycolysis; many viruses similarly reprogram host metabolism toward glycolysis, increasing intracellular lactate that must be effluxed. Unexpectedly, MCT1 inhibitors were ineffective in A549 cells due to compensatory activity of MCT4, as A549 cells express both MCT1 and MCT4, whereas K562 cells express only MCT1. A selective MCT4 inhibitor was inactive in both cell lines, suggesting that simultaneous inhibition of both transporters is required. Accordingly, combined MCT1 and MCT4 inhibition synergistically blocked HAdV infection in both transformed cell types and primary normal human bronchial epithelial cells. These findings underscore the importance of host cell metabolism in HAdV infection and identify MCTs as promising antiviral targets.

Authors

Institutions

Publication Details

Journal
Antimicrobial Agents and Chemotherapy
Published
2026-11-16
DOI
https://doi.org/10.1128/aac.00425-26
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Inhibitors of monocarboxylate transporters as host-directed antivirals against human adenoviruses

Liane Viru, Preeti Iyer, Martina Fitzek, Magnus Evander et al.
1 links
Antimicrobial Agents and Chemotherapy
Virus-based gene therapy research
article

Inhibitors of monocarboxylate transporters as host-directed antivirals against human adenoviruses

Liane Viru, Preeti Iyer, Martina Fitzek, Magnus Evander, Mikael Elofsson, Sara Spjut, Mårten Strand, David M. Smith, Amanda Freitas-Huhtamäki, Marian Preston, Andrew M. Davis
article en

Abstract

Human adenoviruses (HAdVs) are non-enveloped double-stranded DNA viruses that cause a wide range of typically mild, self-limiting infections in humans, but are associated with high morbidity and mortality in immunocompromised individuals. There are currently no approved antivirals specifically targeting HAdV infection. To identify novel anti-adenoviral compounds and host factors critical for infection, we screened a target-annotated library of 13,000 compounds, covering 1,763 known human targets, against HAdV type 11 in K562 cells. This screen yielded numerous anti-adenoviral compounds, many of which were kinase inhibitors, well known to also show antiviral activity. We instead focused on potent and selective inhibitors of monocarboxylate transporter 1 (MCT1) for further investigation. For 25 MCT1 inhibitors, antiviral activity correlated clearly with MCT1 inhibitory potency, indicating MCT1 inhibition as the likely mechanism. MCT1 exports lactate and is frequently overexpressed in cancers that rely on aerobic glycolysis; many viruses similarly reprogram host metabolism toward glycolysis, increasing intracellular lactate that must be effluxed. Unexpectedly, MCT1 inhibitors were ineffective in A549 cells due to compensatory activity of MCT4, as A549 cells express both MCT1 and MCT4, whereas K562 cells express only MCT1. A selective MCT4 inhibitor was inactive in both cell lines, suggesting that simultaneous inhibition of both transporters is required. Accordingly, combined MCT1 and MCT4 inhibition synergistically blocked HAdV infection in both transformed cell types and primary normal human bronchial epithelial cells. These findings underscore the importance of host cell metabolism in HAdV infection and identify MCTs as promising antiviral targets.

Antimicrobial Agents and Chemotherapy
AstraZeneca (United Kingdom) (GB), AstraZeneca (Sweden) (SE), University of Tartu (EE), Umeå University (SE)
Familjen Erling-Perssons Stiftelse, Kempestiftelserna
Good health and well-being
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon